QIAGEN and Servier Will Develop CDx for Acute Myeloid Leukemia Therapy Drug
QIAGEN and Servier are partnering to develop a CDx test for TIBSOVO, an isocitrate dehydrogenase-1 inhibitor indicated for AML treatment.
Read MorePosted by Andy Lundin | Mar 10, 2023 | Leukemia |
QIAGEN and Servier are partnering to develop a CDx test for TIBSOVO, an isocitrate dehydrogenase-1 inhibitor indicated for AML treatment.
Read MorePosted by Andy Lundin | Mar 9, 2023 | Leukemia |
Research shows benefits of screening patients in remission from acute myeloid leukemia for residual disease prior to a bone marrow transplant.
Read MorePosted by Andy Lundin | Mar 2, 2023 | Cancer |
Investigators at Children’s Hospital Los Angeles investigators have developed a liquid biopsy for pediatric solid tumors.
Read MorePosted by Andy Lundin | Feb 16, 2023 | Cancer |
Eurofins launched a test that can assess the expansion and persistence of CAR-T therapy in patients with certain leukemia and lymphomas.
Read MorePosted by Andy Lundin | Feb 6, 2023 | Leukemia |
Identifying recurrent genetic alterations in myeloid neoplasms has improved diagnosis and expanded targeted treatments available to patients.
Read More